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ABSTRACT  
HbA1c is being used to assess the glycemic control for many years. This study was done to evaluate the importance of HbA1c in predicting 
dyslipidemia and atherogenecity in type 2 Diabetes. Methods: 200 type 2 diabetic patients were taken as subjects. Fasting and post meal 
blood sugar, Glycated haemoglobin (HbA1c), lipid profile, lipid ratios and atherogenic index of plasma (AIP) was analysed in these 
patients. The patients were divided into 2 groups depending on their HbA1c; Good Glycemic Control was defined as having HbA1c ≤ 
7.0% and Poor Glycemic Control as HbA1c >7.0%. Results & Discussion: We found a significant increase in the levels of blood glucose, 
total serum cholesterol (TC), triglyceride, LDL cholesterol (LDL-C) and VLDL cholesterol (VLDL-C), TC/HDL-C, LDL-C/HDL-C, 
atherogenic index of plasma (AIP) and a significant decrease in the levels of HDL cholesterol (HDL-C) in patients with HbA1c>7% as 
compared to patients with HbA1c ≤ 7%. HbA1c had a direct and significant correlation with TC, TG, VLDL-C, LDL-C, TC /HDL-C, 
LDL-C/HDL-C, and an inverse correlation with HDL-C. AIP correlates with cardiovascular risk very well, and the association between 
HbA1c with various lipid parameters and atherogenic ratios suggests the importance of glycemic control in order to control dyslipidemia 
and future risk of cardiovascular disease in type 2 diabetics. 
KEYWORDS: Lipid profile, type 2 diabetes mellitus, Glycosylated haemoglobin, glycemic control, atherogenic index of plasma. 
INTRODUCTION 
Diabetes is a global endemic with rapidly increasing prevalence 
in both developed and developing countries and there is a high 
risk of cardiovascular disease (CVD) in people with type 2 
diabetes.[1] Although there is an increase in the prevalence of 
type 1 diabetes also, the major driver of the epidemic is the more 
common form of diabetes, namely type 2 diabetes, which 
accounts for more than 90 per cent of all diabetes cases. The 
International Diabetes Federation (IDF) estimates the total 
number of diabetic subjects to be around 40.9 million in India 
and this is further set to rise to 69.9 million by the year 2025.[2] 
Glycated Hemoglobin (HbA1c) is a routinely used marker for 
long term glycemic control. HbA1c predicts the risk for 
development of diabetic complications in diabetic patients. 
Now-a-days, elevated levels of HbA1c have been regarded as an 
independent risk factor for cardiovascular disease in subjects 
with or without diabetes.[3] The Diabetes complications and 
control trial (DCCT)[4] carried out by National Institute of 
Diabetes and Digestive and Kidney Diseases (NIDDK), USA, 
established that, HbA1c is the gold standard of glycemic control. 
The level of HbA1c value ≤7.0% was said to be appropriate for 
reducing the risk of cardiovascular complications. HbA1c is 
directly related to the severity of coronary artery disease (CAD) 
in diabetic patients. Estimated risk of CAD has shown to be 
increased by 18% for each 1% increase in absolute HbA1c value 
in diabetic population.[5] 
Dyslipidemia is one of the major established risk factors for 
cardiovascular disease in diabetes mellitus.[6] The characteristic 
features of diabetic dyslipidemia are increased levels of 
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triglyceride(TG) concentration and low density lipoprotein 
cholesterol ( LDL-C) particles decreased high density 
lipoprotein cholesterol (HDL-C). Although the major focus is 
on the connection between lipids and CVD is on LDL-C, the 
National Cholesterol Education Program under  Adult 
Treatment Panel III has recognized the important roles of HDL-
C and TGs, calling this combination an atherogenic 
dyslipidemia.[7] 
Individuals with coexisting diabetes and metabolic syndrome 
have the highest prevalence of CVD. Early therapeutic 
interventions, aiming to reduce triglycerides and LDL and to 
increase HDL-C, significantly reduce mortality in type 2 
diabetic patients.[8,9] 
Several lipoprotein-related indices [plasma concentrations of 
lipids (LDL-C, HDL-C, and TGs), molar ratios (TG/HDL-C and 
LDL-C/HDL-C), and particle size (LDL-C and HDL-C) have 
been used to predict CVD risk. The total cholesterol/HDL-C and 
LDL-C/HDL-C molar ratios have good predictive value for 
future cardiovascular events.   
Recently, another molar ratio, log TG/HDL-C popularly known 
as Atherogenic Index of Plasma (AIP), has been used as a 
significant and independent predictor of CHD.[10] AIP has been 
proposed as a predictive marker for plasma atherogenicity and 
is positively correlated with cardiovascular disease risk. AIP's 
significance as a marker is based on the following facts:  
1. It is found increased in cohorts at high risk for CAD;  
2. It is positively correlated with the fractional esterification rate 
of HDL-C (FERHDL), which is perhaps the most dependable 
marker for the atherogenic capacity of the lipid-lipoprotein 
profile; and  
3. It is inversely correlated to LDL-C particle size[11] 
Tan et al.[10] compared the results of AIP analysis with those of 
a TG/HDL-C ratio analysis used in another study.[12] The P 
values for AIP were consistently lower than those for TG/HDL-
C. An AIP of < 0.11 is considered as low risk, 0.11- 0.21 
intermediate risk and  >0.21 as high risk[13,14]. 
With this preview, this study was undertaken with the aim of 
evaluating the importance of HbA1c in predicting the diabetic 
dyslipidemia and atherogenecity. 
MATERIALS AND METHODS 
This study was at done at Indira Gandhi Govt. Medical College 
& Hospital, Nagpur between January 2014 and September 2014 
with 200 diagnosed cases of DM type 2 in the age group of 25-
75 years, attending the diabetic OPD and admitted to the 
medicine wards. Patients with complications like retinopathy, 
nephropathy, history of heart disease, hepatic disorders or any 
other chronic illness were excluded from the study. The 
clearance was taken from the institutional ethical committee. 
Informed and written consent was taken from the patients, with 
the explanation of the procedure of the study. 
The patients were divided into 2 groups depending on the levels 
of glycated hemoglobin (HbA1c); good glycemic control was 
defined as  HbA1c < 7.0%(< 53mmol/mol)  and poor glycemic 
control as  HbA1c >7.0%  (> 53mmol/mol).[15] Venous blood 
samples from all the subjects were collected after at least 8 hours 
fasting and analyzed for fasting plasma glucose (FPG), 2 hours 
post prandial glucose levels(2hPG), serum total 
cholesterol(TC), triglycerides (TG) using kit based method on 
autoanalyser XL-640 Erba. HDL-C was estimated by kit based 
on precipitation method[16] & Very low density lipoprotein 
cholesterol(VLDL-C) & LDL-C analysis was done by applying 
Frieldwald’s formula[17] i.e. VLDL-C = TG/5 where TG is less 
than 400 mg/dl, LDL-C was calculated as : TC - (HDL-C+ 
VLDL-C). HbA1c was calculated by Ion Exchange Resin 
Method, (Accurex Manufacturers). The atherogenic index of 
plasma (AIP) was calculated by the formula base 10 logarithm 
of the ratio of TG to HDL-C.[10] 
For serum lipid reference level, National Cholesterol Education 
Programme (NCEP) Adult Treatment Panel III (ATP III) 
guideline was referred. According to NCEP-ATPIII guidelines, 
hypercholesterolemia is defined as TC >200 mg/dl, high LDL-
C with a value >100 mg/dl, hypertriglyceridemia as TG >150 
mg/dl and low HDL-C with a value <40 mg/dl. Dyslipidemia 
was defined by presence of one or more than one abnormal 
serum lipid concentration.[18] 
STATISTICAL ANALYSIS 
Demographic and lipid parameters were presented as Mean ± 
SD. Categorical variables were expressed in actual numbers and 
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percentage. Demographic and lipid parameters were compared 
by performing unpaired t-test. Categorical variables were 
compared by performing chi-square test.  P value <0.05 was 
considered as statistically significant. Statistical software 
STATA version 12.0 was used for data analysis. 
RESULTS 
Out of the 200 patients studied, there were 74 males and 126 
females. The maximum number of patients were in the age 
group of 51-60 years.  
 Table 1 and Figure 1 shows the comparison of studied 
parameters between the good and poor glycemic control group. 
The levels of FBG, TC, TG,VLDL-C LDL-C, HbA1c, AIP, 
ratios of TC/HDL-C and LDL-C/HDL-C are increased, while 
the levels of HDL-C are decreased in patients with HbA1c >7% 
as compared to patients with HbA1c ≤ 7% and these values are 
highly significant. The patients with HbA1c >7% had 
dyslipidemia as the most prominent feature in the lipid profile. 
This shows that glycemic control is extremely necessary to curb 
the future risk of cardiovascular disease, which can be 
contributed to the atherogenic lipid profile. 
Table 1. Demographic and Lipid parameters categorized 
by patients  glycemic control 
P <0.001- HS (highly significant) 
 
Figure 1. Comparison of lipid and glucose profile in good 
(HbA1c ≤7) & poor (HbA1c >7)  glycemic control group. 
Insulin impacts the liver apolipoprotein production which 
regulates the enzymatic activity of lipoprotein lipase and 
Cholesterol ester transport protein. These could be the likely 
causes of dyslipidemia in Diabetes mellitus as reported by 
Goldberg[19]. Over and above this, insulin deficiency also 
reduces the activity of hepatic lipase and several other steps in 
the production of biologically active lipoprotein lipase may also 
be altered in DM.[20]  A number of studies using tracer kinetics 
in humans have demonstrated that liver production of 
apolipoprotein B (apoB), the major protein component of VLDL 
and LDL, is increased in type 2 diabetes. Increased lipolysis in 
adipocytes due to poor insulinization results in increased fatty 
acid release from fat cells. The ensuing increase in fatty acid 
transport to the liver, which is a common abnormality seen in 
insulin-resistant diabetes, may cause an increase in VLDL 
secretion.[21] A second regulatory process may be a direct effect 
of insulin on liver production of apoB and other proteins 
involved in degradation of circulating lipoproteins. In some 
studies insulin directly increased degradation of newly 
synthesized apoB.[22] Therefore, insulin deficiency or hepatic 
insulin resistance may increase the secretion of apoB, in turn 
increasing LDL-C and VLDL-C levels.  
Table 2 shows direct and significant correlation of HbA1c with 
FBG, 2hPG, as also shown by previous studies.[23,24] It also 
shows  direct and highly significant correlation of HbA1c  with 
TC, TG (figure2), LDL-C (figure 3), TC/HDL-C, LDL-C/HDL-
C  and AIP(figure 4), while Figure 5 shows inverse correlation 
between HbA1c and HDL.  Khan HA et al. also found similar 




≤ 7.0% >7.0% 
Age in years 51.18± 9.32 57.35± 8.40 <0.0001, HS 
FPG 160.38 ±39.51 189.95 ±46.02 <0.0001, HS 
2hPG 215.58 ±63.55 250.21± 55.94 0.0002 
TC 177.76± 25.10 226.82± 42.71 <0.0001, HS 
TG 148.05± 32.96 224.49± 53.29 <0.0001, HS 
VLDL-C 31.86± 6.59 44.96± 10.76 <0.0001, HS 
HDL-C 56.03± 11.98 48.32± 8.78 <0.0001, HS 
LDL-C 89.88± 16.78 131.78± 40.11 <0.0001, HS 
AIP 0.46± 0.11 0.66± 0.15 <0.0001, HS 
TC/HDL-C 3.26 ±0.59 4.87± 1.40 <0.0001, HS 
LDL-C/HDL-
C 
1.68± 0.49 2.85 ±1.14 <0.0001, HS 
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also found a direct and significant correlation of HbA1c with 
AIP, TC/HDL-C and LDL-C/HDL-C ratio. Thus the severity of 
dyslipidemia increases in patients with increased HbA1c value. 
Elevated levels of HbA1c and dyslipidemia are independent risk 
factors of cardiovascular diseases and hence, diabetic patients 
with elevated HbA1c and dyslipidemia are considered as high 
risk group for cardiovascular disease. Improving glycemic 
control can reduce the risk of cardiovascular events in diabetes. 
Table 2. Correlation of HbA1c with FBG, 2hPG and lipid 
parameters 
 P < 0.001- HS (highly significant) 
 
 
Figure 2. Direct correlation between HbA1c & TG levels, 
r=0.73 
 
Figure 3.  Direct correlation between HbA1c & LDL-C 
levels, r= 0.58 
 
Figure 4. Direct correlation between HbA1c & AIP levels, 
r= 0.71 
 
Figure 5. Inverse correlation between HbA1c & HDL-C 
levels, r = - 0.39 
 
Parameters r-value p-value 
FPG 0.4936 <0.0001, HS 
2hPG 0.4084 <0.0001, HS 
TC 0.6607 <0.0001, HS 
TG 0.7273 <0.0001, HS 
VLDL-C 0.7219 <0.0001, HS 
HDL-C -0.3941 <0.0001, HS 
LDL-C 0.5842 <0.0001, HS 
AIP 0.7147 <0.0001, HS 
TC/HDL-C 0.6854 <0.0001, HS 
LDL/HDL-C 0.6040 <0.0001,HS 
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Table 3. Association of AIP and HbA1c  
p< 0.05 - S (significant) 
Table 3 shows that patients with  HbA1c >7% were more prone 
to cardiovascular risk as their levels of AIP fall in the high risk 
group i.e AIP > 0.22  and the association was highly significant 
proving that glycemic control contributes significantly to the 
future risk of cardiovascular problems. We also found that the 
lipid parameters of  patients with HbA1c <7% were in the 
normal range but the AIP levels still fell in the risk group, Table 
1. We hypothesize that even if the lipid profile appears to be in 
normal range, the AIP levels when calculated can be in the risk 
group emphasising the calculation of this simple ratio every time 
a lipid profile is asked for.  AIP, therefore, reflects the delicate 
metabolic interactions within the whole lipoprotein complex.[13] 
DISCUSSION  
In accordance with Dobiasova et al[13] it is observed from table 
3, patients with type 2 diabetes with poor glycemic control have 
the highest AIP. Dobiasova et al. also observed a higher 
FERHDL compared with nondiabetic individuals.[26] In addition, 
they are more likely to have a predominance of small, dense 
LDL particles compared with nondiabetic controls.[27] All of 
these factors suggest that AIP is a suitable marker for plasma 
atherogenicity  and cardiovascular risk in patients with type 2 
diabetes. 
Earlier studies targeted total cholesterol and HDL-C levels to 
reduce the risk for CVD, but the levels of triglyceride were 
ignored as a contributor towards this risk. Since Gaziano et al. 
reported that “the ratio of triglycerides to HDL was a strong 
predictor of myocardial infarction[28],  additional findings have 
been made regarding  relationship between HDL-C and TGs. 
Tan et al.[10] compared the results of AIP analysis with those of 
a TG/HDL-C ratio analysis used in another study.[12]  The P 
values for AIP were consistently lower than those for TG/HDL-
C. 
Although an independent, inverse relationship between HDL-C 
and cardiovascular risk has been demonstrated beyond any 
doubt, the contribution of TGs to cardiovascular risk has been 
underestimated. This may have been attributable to the high 
variability of plasma TG concentrations (which decreases the 
statistical significance of assessments), the lack of information 
on the role of TGs in biochemical mechanisms, or the incessant 
efforts to find an atherogenic marker independent of other lipids. 
In reality, any therapeutic hypolipidemic intervention leads to 
bigger or smaller changes in the spectrum of plasma lipids and 
apoproteins, including changes in lipoprotein particle sizes and 
changes in cholesterol esterification and lipolytic rates.[29] Thus, 
TGs play the role of a regulator of lipoprotein interactions and 
not the role of an independent risk marker. This claim is 
supported by evidence that an increased plasma concentration 
of TGs is associated with (a) an increased incidence of coronary 
artery disease, (CAD)[30] (b) an increased population of small, 
dense LDLs and (c) enhanced cholesteryl ester (CE) mass 
transfer from HDL to apolipoprotein B (apoB)-containing 
lipoproteins.[31]  
CONCLUSION 
It can be concluded from the present study that patients with 
poor glycemic control have a atherogenic lipid profile and 
Glycated haemoglobin predicts dyslipidemia and 
atherogenicity. Atherogenic index of plasma, is an independent 
parameter which correlates very significantly with the 
cardiovascular risk. This parameter is easy to calculate every 
time a lipid profile is asked for, so that the cardiovascular risk 
of the patient can be assessed.  
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<0.11 ( low risk) 0 1  
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